scholarly journals Effect of Muscular Exercise on Patients With Muscular Dystrophy: A Systematic Review and Meta-Analysis of the Literature

2020 ◽  
Vol 11 ◽  
Author(s):  
Silvia Gianola ◽  
Greta Castellini ◽  
Valentina Pecoraro ◽  
Marco Monticone ◽  
Giuseppe Banfi ◽  
...  
2020 ◽  
Vol 35 (7) ◽  
pp. 643-653 ◽  
Author(s):  
Erik Landfeldt ◽  
Rachel Thompson ◽  
Thomas Sejersen ◽  
Hugh J. McMillan ◽  
Janbernd Kirschner ◽  
...  

2014 ◽  
Vol 24 (6) ◽  
pp. 482-491 ◽  
Author(s):  
Jean K. Mah ◽  
Lawrence Korngut ◽  
Jonathan Dykeman ◽  
Lundy Day ◽  
Tamara Pringsheim ◽  
...  

2021 ◽  
Vol 14 (8) ◽  
pp. 798
Author(s):  
Carlos Pascual-Morena ◽  
Iván Cavero-Redondo ◽  
Alicia Saz-Lara ◽  
Irene Sequí-Domínguez ◽  
Maribel Lucerón-Lucas-Torres ◽  
...  

The transforming growth factor beta (TGFβ) pathway could modulate the Duchenne muscular dystrophy (DMD) phenotype. This meta-analysis aims to estimate the association of genetic variants involved in the TGFβ pathway, including the latent transforming growth factor beta binding protein 4 (LTBP4) and secreted phosphoprotein 1 (SPP1) genes, among others, with age of loss of ambulation (LoA) and cardiac function in patients with DMD. Meta-analyses were conducted for the hazard ratio (HR) of LoA for each genetic variant. A subgroup analysis was performed in patients treated exclusively with glucocorticoids. Eight studies were included in the systematic review and four in the meta-analyses. The systematic review suggests a protective effect of LTBP4 haplotype IAAM (recessive model) for LoA. It is also suggested that the SPP1 rs28357094 genotype G (dominant model) is associated with early LoA in glucocorticoids-treated patients. The meta-analysis of the LTBP4 haplotype IAAM showed a protective association with LoA, with an HR = 0.78 (95% CI: 0.67–0.90). No association with LoA was observed for the SPP1 rs28357094. The LTBP4 haplotype IAAM is associated with a later LoA, especially in the Caucasian population, while the SPP1 rs28357094 genotype G could be associated with a poor response to glucocorticoids. Future research is suggested for SPP1 rs11730582, LTBP4 rs710160, and THBS1 rs2725797.


2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Salvatore Crisafulli ◽  
Janet Sultana ◽  
Andrea Fontana ◽  
Francesco Salvo ◽  
Sonia Messina ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e029341 ◽  
Author(s):  
Carlos Pascual Morena ◽  
Vicente Martinez-Vizcaino ◽  
Celia Álvarez-Bueno ◽  
Ruben Fernández Rodríguez ◽  
Estela Jiménez López ◽  
...  

IntroductionIn recent years, important advances have been made in the treatment of Duchenne muscular dystrophy (DMD). This protocol proposes a methodology for carrying out a systematic review and meta-analysis that aims to: (1) improve the evidence of the benefits of different pharmacological treatments in boys with DMD, and (2) compare the benefit of treatments specifically aimed at delaying the progression of disease in the functional outcomes.Methods and analysisThis protocol is guided by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) and by the Cochrane Collaboration Handbook. A thorough selection of the literature will be done through the MEDLINE, EMBASE and Web of Science databases. The search will be conducted in English and Spanish. The Risk of Bias 2.0 tool from the Cochrane Collaboration will be used to assess the risk of bias. A narrative synthesis of the data will be performed. Meta-analysis will be conducted for effect of treatment on the 6 min walking distance (6MWD), North Star Ambulatory Assessment and Timed Functional Tests. Subgroup analyses will be performed by age or baseline values of the 6MWD, and overall bias.Ethics and disseminationThe approval of an ethical committee is not required. All the included trials will comply with the current ethical standards and the Declaration of Helsinki. The results of this proposed systematic review and meta-analysis will provide a general overview and evidence concerning the effectiveness of pharmacological treatments in Duchenne muscular dystrophy. Findings will be disseminated to academic audiences through peer-reviewed publications, as well as to clinical audiences, patients’ associations and policy makers, and may influence guideline developers in order to improve outcomes for these patients.PROSPERO registration numberCRD42018102207


2021 ◽  
Vol 429 ◽  
pp. 118404
Author(s):  
Carlos Alva-Diaz ◽  
Marco Malaga Julca ◽  
Peggy Martinez-Esteban ◽  
Paula Moran Ballon ◽  
Fabian Chavez Ecos ◽  
...  

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
Yuko Shimizu-Motohashi ◽  
Terumi Murakami ◽  
En Kimura ◽  
Hirofumi Komaki ◽  
Norio Watanabe

Sign in / Sign up

Export Citation Format

Share Document